证券代码：002880 证券简称：卫光生物 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 编号：2023-004 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员 | 线上参与公司2022年度网上业绩说明会的全体投资者 | | 姓名 | | | 时间 | 2023年05月16日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/） | | 上市公司接待人员姓名 | 董事长、董事会秘书（代行） 张战先生 | | | 董事、总经理 郭采平女士 | | | 董事、财务总监 岳章标先生 | | | 独立董事 王艳梅女士 公司2022年度业绩说明会采用网络文字互动的方式 | | | 1.请简单介绍一下公司的主要产品 | | | 召开，主要内容如下： | | | 答：尊敬的投资者，您好！公司目前共计拥有人血 | | 投资者关系活动主要 内容介绍 | 白蛋白 ...

Financial Performance - The company's operating revenue for 2022 was ¥667,931,462.81, a decrease of 26.39% compared to ¥907,434,715.73 in 2021[22] - The net profit attributable to shareholders for 2022 was ¥117,443,567.69, down 42.83% from ¥205,436,658.57 in the previous year[22] - The net profit after deducting non-recurring gains and losses was ¥101,133,456.51, a decline of 48.68% from ¥197,069,666.27 in 2021[22] - The basic earnings per share for 2022 was ¥0.5178, representing a decrease of 42.84% compared to ¥0.9058 in 2021[22] - Total revenue for blood products was CNY 653,934,311, a decrease of 26.47% year-on-year, with a gross margin of 35.23%[60] - Revenue from blood products amounted to ¥653,934,311.64, accounting for 97.90% of total revenue, with a decline of 26.47% from ¥889,291,075.59 in the previous year[58] - The company reported a significant reduction in financial expenses, down 74.81% to CNY -1,473,091.67, due to reclassification of interest income[67] - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year growth of 12%[135] Assets and Liabilities - Total assets at the end of 2022 amounted to ¥2,575,733,822.26, an increase of 28.56% from ¥2,003,504,959.66 at the end of 2021[22] - The net assets attributable to shareholders at the end of 2022 were ¥1,840,809,066.12, up 4.08% from ¥1,768,725,498.43 in 2021[22] - The company reported a significant increase in long-term borrowings to ¥428,961,954.68, attributed to fixed asset loans[76] - Short-term borrowings rose to ¥100,086,111.11, reflecting new short-term loans taken during the period[76] - Inventory levels increased to ¥605,510,451.16, representing 23.51% of total assets, driven by higher raw materials and finished goods[76] Cash Flow - The net cash flow from operating activities for 2022 was ¥1,199,043.12, a significant decrease of 99.51% compared to ¥246,886,601.24 in 2021[22] - The net cash flow from investment activities increased by 67.98%, primarily due to increased payments for construction projects[72] - The company reported a net cash flow from operating activities of CNY 52.32 million in the fourth quarter, a turnaround from negative cash flows in the first three quarters[27] Research and Development - The company has established a comprehensive product R&D mechanism, with 41 national authorized patents, including 17 invention patents and 24 utility model patents[52] - Research and development expenses decreased by 24.63% to CNY 35,865,911.95, primarily due to reduced investment in R&D[67] - The R&D expenditure for new products and technologies was 200 million RMB, accounting for 13.3% of total revenue[135] - The company is committed to enhancing its R&D capabilities by improving management mechanisms and optimizing R&D models[106] Market and Competition - The blood products market in China was valued at approximately CNY 40 billion in 2022, with significant growth potential driven by increasing healthcare demands and an aging population[37] - The company aims to expand its market presence by leveraging its technological and brand advantages to drive product exports and explore international markets[40] - Increased competition in the market is anticipated as companies focus on developing products like human fibrinogen and recombinant factor VIII, necessitating optimized marketing strategies and international market exploration[108] Corporate Governance - The company has established effective communication channels with shareholders to ensure their rights are upheld[112] - The company held its first temporary shareholders' meeting on March 24, 2022, with an investor participation rate of 65.36%[126] - The board of directors and management team have remained stable, with no reported changes in senior management during the reporting period[127] - The company has established a comprehensive internal control system that covers all business activities and financial reporting, with no significant omissions identified[160] Environmental and Social Responsibility - The company has complied with all relevant environmental protection laws and obtained necessary permits for its production projects[168] - The company reported no instances of exceeding pollution discharge limits in its operations[169] - The company has contributed a total of 846,100 RMB to poverty alleviation efforts, including 504,800 RMB for educational donations and 221,300 RMB for purchasing agricultural products from supported areas[180] - The company actively engages in social welfare activities, with nearly 150 registered volunteers contributing over 1,400 service hours[179] Future Plans and Strategies - The company plans to launch new products, including human prothrombin complex and human factor VIII, expected to be approved for sale in 2023, which will enhance the utilization rate of raw plasma[68] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[135] - The company aims to leverage capital markets for development, including targeted stock issuance and acquisitions of quality assets in the industry[102] - The company plans to enhance its product portfolio with new vaccines and therapies, which are expected to strengthen its competitive position and overall profitability[69]

Financial Performance - The company's revenue for Q1 2023 was CNY 208,518,007.07, representing a 51.34% increase compared to CNY 137,783,337.47 in the same period last year[4] - Net profit attributable to shareholders was CNY 45,736,044.33, an increase of 80.54% from CNY 25,333,345.87 year-on-year[4] - Basic earnings per share rose to CNY 0.2017, up 80.57% from CNY 0.1117 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached ¥208,518,007.07, a significant increase of 51.2% compared to ¥137,783,337.47 in Q1 2022[16] - Net profit for Q1 2023 was ¥45,625,876.61, representing a 80.9% increase from ¥25,205,287.60 in Q1 2022[17] - Earnings per share (EPS) for Q1 2023 was ¥0.2017, compared to ¥0.1117 in the same period last year, reflecting a 80.5% increase[18] - The total comprehensive income for Q1 2023 was ¥45,625,876.61, compared to ¥25,205,287.60 in Q1 2022, showing a strong growth trajectory[18] Cash Flow - The net cash flow from operating activities reached CNY 51,288,202.98, a significant improvement from a negative CNY 5,378,157.74 in the previous year, marking a 1,053.64% increase[4] - Cash inflow from operating activities totaled ¥258,633,808.51, an increase from ¥182,856,172.52 in Q1 2022[19] - The net cash flow from operating activities for Q1 2023 was ¥51,288,202.98, compared to a negative cash flow of ¥5,378,157.74 in the same period last year[20] - The net cash flow from investing activities was negative at ¥81,871,610.61, a decrease from the previous year's negative cash flow of ¥56,440,030.96[20] - The net cash flow from financing activities was positive at ¥47,169,380.45, down from ¥162,125,824.98 in Q1 2022[20] - The net increase in cash and cash equivalents for Q1 2023 was ¥16,585,972.82, compared to an increase of ¥100,307,636.28 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,656,276,378.90, a 3.13% increase from CNY 2,575,733,822.26 at the end of the previous year[4] - Total assets as of March 31, 2023, amounted to ¥2,656,276,378.90, up from ¥2,575,733,822.26 at the beginning of the year, indicating a growth of about 3.1%[14] - Total liabilities decreased from ¥229,755,503.63 to ¥211,557,179.25, a reduction of approximately 7.9%[14] - Total liabilities increased to ¥743,116,795.21 from ¥708,199,697.29, reflecting a growth of 4.9% year-over-year[17] - Total equity attributable to shareholders reached ¥1,886,545,110.45, up from ¥1,840,809,066.12, marking a growth of 2.5%[17] Operating Costs and Income - The company reported a 54.51% increase in operating costs, totaling CNY 121,477,101.04, primarily due to increased sales volume[6] - Operating costs amounted to ¥155,644,988.93, up 42.3% from ¥109,391,163.31 in the previous year, with operating costs per revenue decreasing[16] - Other income increased by 42.48% to CNY 2,634,046.04, mainly due to higher government subsidies received[7] - The company reported a significant increase in other income to ¥2,634,046.04 from ¥1,848,731.39, indicating improved financial performance[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,140[9] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of shares, totaling 147,987,000 shares[9] - The company has no preferred shareholders as of the reporting period[11] Research and Development - Research and development expenses were ¥10,819,588.91, slightly up from ¥10,460,066.69 in the previous year, indicating continued investment in innovation[16] Other Information - The company has initiated a share acquisition plan as of January 10, 2023, and a non-public stock issuance plan on March 30, 2023[11] - The first phase employee stock ownership plan holds 820,890 shares, representing a small portion of the total shares[10] - The company did not conduct an audit for the Q1 2023 report[21] - The report was presented by the board of directors on April 24, 2023[22]

深圳市卫光生物制品股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）2022 年年度报告已于 2023 年 4 月 26 日刊登于巨潮资讯网(www.cninfo.com.cn)。为便于广大投资者更 加全面深入地了解公司 2022 年度经营业绩、发展战略等情况，公司拟于 2023 年 5 月 16 日（星期二）举办业绩说明会。具体情况如下： 一、网上业绩说明会的安排 证券代码:002880 证券简称:卫光生物 公告编号:2023-023 （一）会议召开时间：2023 年 5 月 16 日（星期二）15:00-17:00 （二）会议召开方式：网络互动方式 （三）会议召开网址：价值在线(www.ir-online.cn) （四）出席本次业绩说明会的人员：公司董事长、董事会秘书（代行）张战 先生；董事、总经理郭采平女士；董事、财务总监岳章标先生；独立董事王艳梅 女士。 二、征集问题事项及投资者参加方式 投资者可于2023年5月16日15:00-17:00通过网址h ...

Group 1: Company Overview and Competitive Advantages - The company ranks among the industry leaders in average plasma collection volume per station in 2021, with a high blood plasma utilization rate and strong operational capabilities [2] - In 2022, the company signed a cooperation agreement with the Russian government for the production and technology transfer of human blood albumin and intravenous immunoglobulin [2] - The company is focused on building the "Weiguang" brand, which has gained market recognition for its product quality [2] - The Weiguang Life Science Park aims to establish a diversified biopharmaceutical platform, targeting the global forefront of biotechnology [3] Group 2: Weiguang Life Science Park Development - The park is positioned to leverage the Greater Bay Area and Shenzhen's dual-zone drive, focusing on synthetic biology and neuroscience as key areas [3] - It aims to create a research economic ecosystem characterized by innovation incubation and achievement transformation [3] - The park will support the growth of innovative projects and establish a health ecosystem by linking industry resources [3] Group 3: Product Pricing and Production Capacity - The company maintains stable factory prices for its main products, such as human blood albumin and intravenous immunoglobulin, with minimal fluctuations [3] - Following a technological transformation of production lines in 2022, the company has seen a slight increase in plasma collection volume in the first half of 2022 [3] - The Pingguo plasma station, located in Guangxi, has achieved leading industry collection volumes due to effective local donor engagement strategies [3] Group 4: Future Plans and Expansion - The Ankang plasma station will commence operations as soon as it obtains the necessary licenses [3] - The company has plans to establish new plasma stations during the 14th Five-Year Plan period [3]

Group 1: Financial Performance - The company's blood product business achieved revenue of 8.21 billion yuan, representing a growth of 19.41% compared to the previous year [1][2] - The net profit attributable to shareholders was 1.71 billion yuan, reflecting a year-on-year increase of 9.39% [2] - The company expects a 5% increase in plasma collection volume in 2020, targeting a total of 420 tons [7] Group 2: Growth Factors - The company maintained a 100% qualification rate for batch approvals [2] - Plasma collection volume increased by approximately 6% in 2019, with the company’s plasma stations having a leading average collection capacity in the industry [2] - The marketing center strategically adjusted customer structure, optimizing distributor channels and actively exploring overseas markets [2] Group 3: Development Advantages - The company benefits from its location in Shenzhen, within the "Guangdong-Hong Kong-Macao Greater Bay Area" and "Pilot Demonstration Zone" [3] - With over 30 years of experience in the blood product industry, the company has a significant competitive edge [3] - The first major shareholder is the Guangming District State-owned Assets Supervision and Administration Commission, enhancing investor confidence [3] Group 4: Strategic Planning - Future strategies include expanding the main business, increasing production scale, and enhancing product quality [3] - The company plans to utilize the public platform for mergers and acquisitions to broaden its business scope [3] Group 5: Impact of COVID-19 - The demand for blood products, especially immunoglobulin, has significantly increased due to the pandemic [2] - The company’s plasma stations resumed operations in early March 2020, with stable annual plasma collection expected [4] Group 6: Challenges and Solutions - The company faces lower net and gross profit margins compared to peers due to market factors and rising production costs [5] - Marketing reforms in 2019 included structural adjustments and establishing key sales areas, yielding positive results [5] Group 7: Research and Development - Ongoing projects include human fibrinogen and human prothrombin complex, with clinical trials and regulatory submissions planned for 2020 [6]

证券代码：002880 证券简称：卫光生物 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 编号：2020-002 | --- | --- | --- | --- | |------------------------|-------------------------|--------------------------------------------|-------------------------------------------------------| | | | | | | | □ | | 特定对象调研 □分析师会议 | | 投资者关系活动类别 | □ | 媒体采访 √业绩说明会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他 | | | 会议名称 | 卫光生物 2019 | | 年度业绩说明会 | | 参与单位名称及人员姓名 | 参与公司 2019 | | 年度业绩网上说明会的投资者 | | 时间 | 2020 年 3 月 12 | | 日 15:00-17:00 | | | | | | | | | | 全 景 网 " 全 景 • 路 演 天 下 " 投 资 者 ...

投资者来访接待活动记录表 证券代码：002880 证券简称：卫光生物 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|------------------------------------|-------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | √ 业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | 参与公司 2018 | 年度业绩网上说明会的投资者 | | 时间 | 2019 年 4 月 18 | 日 15:00-17:00 | | 地点 | | 全 景 网 " 全 景 • 路 演 天 下 " 投 资 者 互 动 平 台 | | | （ http://rs. p5w.net | ） | | | | （本次业绩说明会采用网络远程方式举行） | | ...